Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2022 May ASCO GI 2022 Lenvatinib plus transarterial chemoembolisation improves clinical outcomes in patients with ad... Read more
2022 May ASCO GU 2022 Promising antitumour activity with neoadjuvant enfortumab vedotin in cisplatin-ineligible musc... Read more
2021 June EADO 2021 Comparison of triplet combinations with BRAF/MEK and PD-(L)1 inhibitors for advanced BRAFV600 ... Read more
2021 June EADO 2021 The impact of age on treatment decisions in high-risk and metastatic melanoma Read more
2021 June EADO 2021 Circulating tumour DNA as a diagnostic, prognostic and predictive tool for melanoma patients? Read more